Table S1. Clinco-pathological characteristics of 200 consecutive advanced NSCLC patients treated with single agent immune checkpoint inhibitors.
| Characteristics | # patients | % |
|---|---|---|
| Total | 200 | 100 |
| Female | 70 | 35 |
| Median age [IQR] | 67 [60–74] | |
| Pack-year [IQR] | 35 [20–50] | |
| Histology | ||
| Adenocarcinoma | 130 | 65 |
| Squamous cell carcinoma | 48 | 24 |
| Others | 21 | 11 |
| Stage | ||
| IIIB–IIIC | 5 | 2.5 |
| IV | 195 | 97.5 |
| ECOG-PS | ||
| 0 | 58 | 29 |
| 1 | 113 | 56.5 |
| 2 | 29 | 14.5 |
| PD-L1 | ||
| ≥50% | 53 | 26.5 |
| <50% | 111 | 55.5 |
| N.A. | 36 | 18 |
| IO as first line therapy | 70 | 35 |
| Presence of liver metastasis | 35 | 17.5 |
| Median NLR (IQR) | 4.2 (2.8–6.8) | |
| Median LDH (IQR) | 361 (309–445) | |
| Median follow-up for alive pts | 14.9 (7.5–26.0) |
NSCLC, non-small cell lung cancer; IQR, interquartile range; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; PD-L1, programmed death-ligand 1; IO, immunotherapy; NLR, neutrophil-to-lymphocyte ratio; LDH, lactate dehydrogenase level.